J Clin Oncol 2021 Aug 2
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.
Related Questions
Does reducing the rate of infusion, or adding Montelukast reduce chances of future reactions?
New answer by Medical Oncologist at Georgetown University Hospital (January 28, 2024)
Fortunately, G3+ infusion reactions with amivantamab are uncommon. In the CHYSALIS phase I study which led to approval for EGFR exon 20 (Park et al., PMID 34339292), G3+ infus...
New answer by Medical Oncologist at Fox Chase Cancer Center (July 19, 2024)
EGFR insertion 20 mutations are a rare subset of adenocarcinoma (1-2%). Patients with disease characterized by these mutations do not respond to EGFR TKIs such as osimertinib....